Stanford School of Medicine
-
Genetics
Risk of secondary cancer after CAR-T cell therapy is low, according to major Stanford Medicine study
Researchers analyzed outcomes for 724 people treated with CAR-T cell therapy at Stanford Health Care between 2016 and 2024. Among…
Read More »